Back to search results

Study on Opioid and Benzodiazepine Polydrug Abuse

This study is looking at how using both opioids (like morphine) and benzodiazepines (like alprazolam) affects people. Researchers want to understand the emotional, thinking, and behavioral changes that happen when these drugs are used together. You would receive either morphine, alprazolam, both together, or a placebo (an inactive substance like a sugar pill). The study aims to see how these different drug combinations affect your anxiety, positive feelings, and negative feelings over about three weeks. This study is for adults aged 18-65 who have used opioids and sedatives in the past, or alcohol frequently. The current status of this study is unclear, and it plans to enroll 24 participants.

Study design
This is an interventional study planning to enroll 24 participants. It will involve giving participants different drug combinations, including morphine, alprazolam, and a placebo.
What's involved
You would participate in 6 laboratory sessions over about three weeks. During these sessions, your anxiety and feelings will be measured after receiving the study drugs.
Compensation
Not stated in the trial record.
Follow-up
Your state anxiety, positive affect, and negative affect will be measured within each of the 6 laboratory sessions over about three weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05006079

Opioid/Benzodiazepine Polydrug Abuse: Aim 3

Recruiting
PHASE2Ages 18–65InterventionalBasic science
Wayne State University
~24 participants
Updated 2025-12-30 on ClinicalTrials.gov
What's tested:MorphineAlprazolamPlacebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
State anxiety
Measured over within-session peak change from pre-drug baseline to 15-120 min post-drug 1 and 15-240 min post-drug 2 administration; measured in each of the 6 laboratory sessions over about 3 weeks
+2 more outcomes measured

Conditions

Opioid Abuse
Benzodiazepine Abuse
Polysubstance Abuse

Explore related trials

Harmful pattern of use of multiple substancesOpioid Use DisorderSedative use disorder

Where it's being run

1 sites across 1 states
Michigan1

Study leadership

  • Mark K Greenwald, PhD · PRINCIPAL_INVESTIGATOR · Wayne State University

Who to contact

Mark K Greenwald, PhD
[email protected]
313-993-3965
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

must self-report past 10-year experience taking opioid and sedative drugs (for therapeutic or non-therapeutic reasons), but not necessarily at the same time. As an alternative to the sedative drug exposure requirement, participants must have used alcohol on at least 3 separate days during the past month. Participants may have current mild- or moderate-severity Opioid Use Disorder or current mild- or moderate-severity Sedative Use Disorder;
must not be seeking treatment for their substance use problems;
must be in current good overall health

Exclusion

meet DSM-5 criteria for current psychosis, bipolar disorder, or severe depression (i.e. severe psychiatric disorder);
meet DSM-5 criteria for severe substance use disorder for any substance (e.g. Sedative, Opioid, Alcohol);
past-month benzodiazepine or opioid prescription (which would suggest daily use, tolerance, or withdrawal upon cessation);
report of past-year any-drug overdose or suicide attempt/ideation;
exhibit cognitive impairment (IQ \< 80 on the Shipley Institute of Living Scale);
neurological, cardiovascular, pulmonary, or systemic diseases (see specific exclusionary conditions under Protection of Human Subjects);
body mass index \> 38 kg/m2;
females who are pregnant (urine), lactating or heterosexually active (self-report) and not using medically approved birth control;
treatment with methadone, buprenorphine or naltrexone;
past 30-day use of contraindicated medications;
alcohol-positive breath sample (\>.02% breath alcohol concentration);
urine sample positive for methadone, cocaine, amphetamines, or barbiturates (\<300 ng/ml)
intolerance of lactose

What this trial measures

  • State anxietywithin-session peak change from pre-drug baseline to 15-120 min post-drug 1 and 15-240 min post-drug 2 administration; measured in each of the 6 laboratory sessions over about 3 weeks

    State Trait Anxiety Inventory - state anxiety scale total score

  • Positive affectwithin-session peak change from baseline to 15-120 min post-drug 1 and 15-240 min post-drug 2 administration; measured in each of the 6 laboratory sessions over about 3 weeks

    Positive and Negative Affect Scale-Short Form (PANAS-SF) positive affect scale score

  • Negative affectwithin-session peak change from baseline to 15-120 min post-drug 1 and 15-240 min post-drug 2 administration; measured in each of the 6 laboratory sessions over about 3 weeks

    Positive and Negative Affect Scale-Short Form (PANAS-SF) negative affect scale score